Trials / Completed

CompletedNCT06712550

Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia

Assessment of Maternal and Fetal Serum Soluble Fms-like Tyrosine Kinase-1, Seromucoid, and Protein-bound Hexose in Women With Pre-eclampsia: A Case-control Study

Status: Completed
Phase: —
Study type: Observational
Enrollment: 204 (actual)

Sponsor: SHAHLA KAREEM ALALAF · Academic / Other
Sex: Female
Age: 18 Years – 45 Years
Healthy volunteers: —

Summary

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

Detailed description

Preeclampsia is a pregnancy-specific hypertension illness that is characterized by widespread maternal endothelial dysfunction and appears to be a systemic syndrome that originates in the placenta. Through binding to and blocking the interaction of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) with their receptors Flt1, soluble fms-like tyrosine kinase (sFlt1) functions as an antagonist of these growth factors. Most seromucoid and protein-bound hexose are released during an acute phase and are inflammatory glycoproteins. Hepatocytes in the liver, which are highly sensitive to stress, increase and leak into the bloodstream during any disease state. It is a time when the placenta demands more vascular development. In order to identify and explain the differences in sFLT-1, VEGF, PlGF levels, and inflammatory biomarker responses. Current study will investigate the differences in blood level of sFLT-1, VEGF, PLGF, Seromucoid and protein-bound hexose inflammatory biomarkers between those with PE (cases) and healthy pregnant women (controls).

Conditions

Timeline

Start date: 2024-12-13
Primary completion: 2025-07-03
Completion: 2025-07-12
First posted: 2024-12-02
Last updated: 2025-07-16

Locations

1 site across 1 country: Iraq

Source: ClinicalTrials.gov record NCT06712550. Inclusion in this directory is not an endorsement.